Carmen Agustín-Pavón

Carmen Agustín-Pavón

Auto-generated profile, based on publicly available information

Carmen Agustín-Pavón

Universitat de València

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2013 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ABArnau Busquets-Garcia
Arnau Busquets-Garcia
MGMaria Gomis-González
Maria Gomis-González
TGThomas Guegan
Thomas Guegan
CACarmen Agustín-Pavón
Carmen Agustín-Pavón
APAntoni Pastor
Antoni Pastor
Andres OzaitaAndres Ozaita
Andres Ozaita

27 September 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MGMireia Garriga-Canut
Mireia Garriga-Canut
CACarmen Agustín-Pavón
Carmen Agustín-Pavón
FHFrank Herrmann
Frank Herrmann
ASAurora Sánchez
Aurora Sánchez
MDMara Dierssen
Mara Dierssen
MIMark Isalan
Mark Isalan
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by expanded CAG repeats in the huntingtin ( HTT ) gene. Although several palliative treatments are available, there is currently no cure and patients generally die 10–15 y after diagnosis. Several promising approaches for HD therapy are currently in development, including RNAi and antisense analogs. We developed a complementary strategy to test repression of mutant HTT with zinc finger proteins (ZFPs) in an HD model. We tested a “molecular tape measure” approach, using long artificial ZFP chains, designed to bind longer CAG repeats more strongly than shorter repeats. After optimization, stable ZFP expression in a model HD cell line reduced chromosomal expression of the mutant gene at both the protein and mRNA levels (95% and 78% reduction, respectively). This was achieved chromosomally in the context of endogenous mouse HTT genes, with variable CAG-repeat lengths. Shorter wild-type alleles, other genomic CAG-repeat genes, and neighboring genes were unaffected. In vivo, striatal adeno-associated virus viral delivery in R6/2 mice was efficient and revealed dose-dependent repression of mutant HTT in the brain (up to 60%). Furthermore, zinc finger repression was tested at several levels, resulting in protein aggregate reduction, reduced decline in rotarod performance, and alleviation of clasping in R6/2 mice, establishing a proof-of-principle for synthetic transcription factor repressors in the brain.

25 June 2009 in Behavioural Brain Research
Verified
Journal Article
Closed access
FMFerran Martínez-García
Ferran Martínez-García
JMJoana Martínez-Ricós
Joana Martínez-Ricós
CACarmen Agustín-Pavón
Carmen Agustín-Pavón
JMJose Martinez-Hernandez
Jose Martinez-Hernandez
ANAmparo Novejarque
Amparo Novejarque
ELEnrique Lanuza
Enrique Lanuza

1 August 2012 in Biological Psychiatry
Verified
Journal Article
Closed access
CACarmen Agustín-Pavón
Carmen Agustín-Pavón
KBKatrin Braesicke
Katrin Braesicke
YSYoshiro Shiba
Yoshiro Shiba
ASAndrea M. Santangelo
Andrea M. Santangelo
YMYevheniia Mikheenko
Yevheniia Mikheenko
ARAngela Roberts
Angela Roberts

20 September 2015 in Brain Structure and Function
Verified
Journal Article
Closed access
PDF file
MOMarcos Otero-García
Marcos Otero-García
CACarmen Agustín-Pavón
Carmen Agustín-Pavón
ELEnrique Lanuza
Enrique Lanuza
FMFerran Martínez-García
Ferran Martínez-García

6 September 2016 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
CACarmen Agustín-Pavón
Carmen Agustín-Pavón
MMMichal Mielcarek
Michal Mielcarek
MGMireia Garriga-Canut
Mireia Garriga-Canut
MIMark Isalan
Mark Isalan
Synthetic zinc finger (ZF) proteins can be targeted to desired DNA sequences and are useful tools for gene therapy. We recently developed a ZF transcription repressor (ZF-KOX1) able to bind to expanded DNA CAG-repeats in the huntingtin (HTT) gene, which are found in Huntington’s disease (HD). This ZF acutely repressed mutant HTT expression in a mouse model of HD and delayed neurological symptoms (clasping) for up to 3 weeks. In the present work, we sought to develop a long-term single-injection gene therapy approach in the brain. Since non-self proteins can elicit immune and inflammatory responses, we designed a host-matched analogue of ZF-KOX1 (called mZF-KRAB), to treat mice more safely in combination with rAAV vector delivery. We also tested a neuron-specific enolase promoter (pNSE), which has been reported as enabling long-term transgene expression, to see whether HTT repression could be observed for up to 6 months after AAV injection in the brain. After rAAV vector delivery, we found that non-self proteins induce significant inflammatory responses in the brain, in agreement with previous studies. Specifically, microglial cells were activated at 4 and 6 weeks after treatment with non-host-matched ZF-KOX1 or GFP, respectively, and this was accompanied by a moderate neuronal loss. In contrast, the host-matched mZF-KRAB did not provoke these effects. Nonetheless, we found that using a pCAG promoter (CMV early enhancer element and the chicken β-actin promoter) led to a strong reduction in ZF expression by 6 weeks after injection. We therefore tested a new non-viral promoter to see whether the host-adapted ZF expression could be sustained for a longer time. Vectorising mZF-KRAB with a promoter-enhancer from neuron-specific enolase (Eno2, rat) resulted in up to 77 % repression of mutant HTT in whole brain, 3 weeks after bilateral intraventricular injection of 1010 virions. Importantly, repressions of 48 % and 23 % were still detected after 12 and 24 weeks, respectively, indicating that longer term effects are possible. Host-adapted ZF-AAV constructs displayed a reduced toxicity and a non-viral pNSE promoter improved long-term ZF protein expression and target gene repression. The optimized constructs presented here have potential for treating HD.